RecruitingNot ApplicableNCT04123535

Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma


Sponsor

Matthew Bucknor

Enrollment

20 participants

Start Date

Jan 23, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a single site, single-arm, feasibility study to evaluate the safety and efficacy of MRgFUS using the ExAblate 2100 System for the partial ablation of undifferentiated pleomorphic sarcomas.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether focused ultrasound — a non-invasive technology that uses sound waves to heat and treat a tumour — can stimulate the immune system to attack undifferentiated pleomorphic sarcoma (UPS), a rare and aggressive soft tissue cancer. The hope is that treating one tumour site may help the immune system fight cancer elsewhere in the body. **You may be eligible if...** - You are 18 years old or older - You have been recently diagnosed with UPS (within the last 6 months) or have a suspected recurrence confirmed by scan - Your tumour is between 2 cm and 20 cm in size and is located in the chest, abdomen, pelvis, or limbs - Your tumour is clearly visible on MRI and is more than 1 cm from any vital structure (nerves, blood vessels, bowel, or skin) - You are in good physical condition (ECOG 0 or 1) - If newly diagnosed, your tumour is considered surgically removable **You may NOT be eligible if...** - Your tumour is less than 2 cm or greater than 20 cm - Your tumour is too close to critical structures or cannot be seen on MRI - You are not in good enough physical condition (ECOG 2 or above) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)

The ExAblate 2100 MRgFUS system (InSightec, Inc., Dallas, Texas, USA) is a noninvasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.14-16 The ExAblate combines a focused ultrasound surgery (FUS) delivery system and a conventional diagnostic 3T Magnetic Resonance (MR) scanner. The ExAblate systems provide a real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control. The ExAblate transducer device is an integrated component of the MR table


Locations(1)

University of California, San Francisco

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04123535


Related Trials